Paper Details

  1. Home
  2. Paper Details

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Author: , AlbrechtJ, BodenheimerH C, DavisG L, DienstagJ L, FeitD, GibasA, JacobsonI M, KuhnsM, LefkowitchJ, LindsayK, MeschievitzC, O'BrienC, PayneJ, PerrilloR P, SamplinerR, SanghviB, SchiffE R, TamburroC

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study compared different treatments for chronic hepatitis B, including interferon alone and in combination with prednisone, to a placebo and no treatment.
Paper Details　
Original Abstract of the Article :
Chronic hepatitis B is a common and often progressive liver disorder for which there is no accepted therapy. To assess the efficacy of treatment with interferon, we randomly assigned patients with chronic hepatitis B to one of the following regimens: prednisone for 6 weeks followed by 5 million unit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJM199008023230503

データ提供：米国国立医学図書館（NLM）

Treating Chronic Hepatitis B: A Randomized Trial of Interferon Alfa-2b

Chronic hepatitis B, a persistent foe in the world of liver health, continues to pose a significant challenge for medical professionals. This randomized controlled trial delves into the efficacy of interferon alfa-2b in treating this condition. The authors, like intrepid researchers venturing into the desert of clinical trials, explore the impact of interferon alfa-2b on patients with chronic hepatitis B.

The study, like a well-conducted expedition, compares the effectiveness of interferon alfa-2b to placebo and examines the impact of different treatment durations. The results provide valuable insights into the potential of interferon alfa-2b as a treatment option for chronic hepatitis B.

Interferon Alfa-2b: A Potential Treatment for Chronic Hepatitis B

This trial, like a beacon of hope in the desert of chronic hepatitis B, explores the potential of interferon alfa-2b as a treatment option. The results offer a glimmer of optimism in the fight against this persistent foe. However, the study also highlights the need for further research to optimize treatment strategies and identify the most effective dosage and duration of interferon alfa-2b therapy.

Understanding Hepatitis B: A Crucial Step in Prevention and Treatment

This research underscores the importance of understanding hepatitis B, a condition that can have long-term consequences for liver health. It emphasizes the need for effective prevention strategies, such as vaccination, and the importance of early detection and treatment. By understanding the disease and its potential complications, we can empower individuals to make informed choices about their health.

Dr. Camel's Conclusion

The desert of hepatitis B research is vast, but this trial offers a valuable landmark. While interferon alfa-2b shows promise as a treatment option, more research is needed to optimize its use. This study reinforces the importance of continued research and a comprehensive approach to managing this challenging condition. By working together, like a caravan traversing the desert, we can find new solutions and improve the lives of patients with chronic hepatitis B.

Date :
  1. Date Completed 1990-08-15
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

2195346

DOI: Digital Object Identifier

10.1056/NEJM199008023230503

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.